August 7, 2024 09:03 AM EDTUpdated 06:19 PM
Pharma
FDA+

In­spec­tion de­lays hold back BeiGene's Tevim­bra progress once again

Max Bayer

Pharma Reporter

BeiGene will need to wait a bit longer for an FDA de­ci­sion on can­cer im­munother­a­py, Tevim­bra, cit­ing a de­lay in sched­ul­ing clin­i­cal site in­spec­tions. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times